TY - JOUR T1 - Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 6879 LP - 6886 VL - 37 IS - 12 AU - SIMON DUCOULOMBIER AU - FRANÇOIS GOLFIER AU - OLIVIER COLOMBAN AU - DAVID BENAYOUN AU - PIERRE-ADRIEN BOLZE AU - MICHEL TOD AU - BENOIT YOU Y1 - 2017/12/01 UR - http://ar.iiarjournals.org/content/37/12/6879.abstract N2 - Aim: To investigate the prognostic value of modeled CA-125 kinetic parameters regarding surgery outcomes and time to second-line chemotherapy in a population of ovarian cancer patients treated with neoadjuvant chemotherapy followed by interval cytoreduction. Patients and Methods: This retrospective study included consecutive patients with FIGO stage IIIc/IV ovarian cancer treated between 2006 and 2014. We characterized CA-125 kinetics and identified modeled kinetic parameters. Results: Fifty four patients were included. KELIM (modeled CA-125 elimination rate constant) was an independent predictive parameter of optimal cytoreduction (OR=0.18; 95% CI=0.04-0.69; p=0.02). In the optimal cytoreduction population (40 patients, 74.1%), E50 (concentration producing 50% of the maximum chemotherapy effect) was a significant prognostic parameter regarding time to second-line chemotherapy (HR=0.38; 95% CI=0.173-0.854; p=0.019). Conclusion: We identified CA-125 modeled kinetic parameters during neoadjuvant chemotherapy harboring potential predictive values regarding the likelihood of optimal cytoreduction, along with time to second-line chemotherapy in optimally-cytoreduced patients. ER -